

July 14, 2023

To,  
National Stock Exchange of India Limited  
Exchange Plaza  
Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051

BSE Limited  
Phiroze Jeejeeboy Towers  
Dalal Street,  
Mumbai- 400 001

**Scrip Symbol: THYROCARE**

**Script Code: 539871**

Dear Sir/Madam,

**Sub: Intimation under Regulation 30 and Regulation 30A in the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time (“Listing Regulations”)**

Pursuant to recent amendments in Regulation 30 and insertion of new Regulation 30A in of the Listing Regulation vide SEBI notification dated June 14, 2023, we, Thyrocare Technologies Limited (“**the Company**”), wish to inform and submit that:

1. The Company has agreed to avail equipments financing facility of INR 45 crores from HDFC Bank Limited on April 11, 2023, pursuant to approval of Board of Directors at its meeting held on April 7, 2023. The purpose of this facility is to meet the funding requirements to complete the acquisition of lab equipments. The Company has created charge by way of hypothecation on its equipments and current assets to secure the loan amount. The total draw down amount under said facility as on date of this letter is INR 26,78,23,800/-; and
2. Docon Technologies Private Limited (“**Docon**”), the promoter company of the Company, has encumbered its entire shareholding i.e. 3,76,56,092 shares in the Company during the financial year 2022-23 in favour of Vistra ITCL (India) Limited (acting in its capacity as debenture trustee) for debentures issued by API Holdings Limited, a promoter group company of the Company pursuant to unattested share pledge agreement executed amongst Docon and the debenture trustee dated June 20, 2022.

The said creation of encumbrance on shares of the Company was duly reported to the Stock Exchanges and to the Company by Docon as per the provisions of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The details of agreement can be accessed on the website of the Company at <https://investor.thyrocare.com/disclosure-under-regulation-30a-of-sebi-lodr/>.



Tests you can trust

In view of recent amendments in Regulation 30, the disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Master circular dated July 11, 2023 for compliance with the provisions of Listing Regulations, is enclosed herewith as "**Annexure A**".

This is for your information and records.

Yours Faithfully,  
For **Thyrocare Technologies Limited**,

**Ramjee Dorai**  
**Company Secretary and Compliance Officer**

**Annexure A**

**Disclosure as per Regulation 30 of the Listing Regulations read with SEBI Master circular dated July 11, 2023 for compliance with the provisions of Listing Regulations:**

<b>Particulars</b>	<b>Details</b>
Name(s) of parties with whom the loan agreement is entered	HDFC Bank Limited
Purpose of entering into the agreement	To acquire of lab equipments
Shareholding, if any, in the entity with whom the agreement is executed	Nil
Significant terms of the agreement	Loan Amount: INR 45 Crores Rate of interest: 8.25 % (Linked to T-Bills) Security: Hypothecation on equipments and current assets Tenure of loan: 3 years
Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arms length	Not a related party transaction

**For Thyrocare Technologies Limited,**

**Ramjee Dorai**  
**Company Secretary and Compliance Officer**